Please login to the form below

Not currently logged in
Email:
Password:

MEDI8897

This page shows the latest MEDI8897 news and features for those working in and with pharma, biotech and healthcare.

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

In 2017, AZ and Sanofi teamed up to develop and commercialise nirsevimab – then known as MEDI8897 – for the prevention of LRTI caused by RSV.

Latest news

  • US, EU regulators back rapid reviews of AZ’s RSV med US, EU regulators back rapid reviews of AZ’s RSV med

    MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Sanofi paid 120m upfront for a share in MEDI8897 last year with another 495m in development and

  • AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

    There’s also provision for up to $470m in sales milestones ties to Synagis, plus a $175m payment due on the US filing for MEDI8897 and another $170m ties to sales ... The Synagis and MEDI8897 deals continues AZ’s policy of focusing firmly on a few

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Sanofi is already active in this category after licensing rights to AstraZeneca’s phase II candidate MEDI8897 last year, with both projects aimed at providing treatment for already-established RSV infections.

  • Regeneron drops RSV drug Regeneron drops RSV drug

    The failure of suptavumab to hit the mark in the NURSERY study removes a potential rival for AstraZeneca's RSV candidate MEDI8897 - recently partnered with Sanofi - which is currently in phase

  • Sanofi buys into AZ drug for preventing RSV infections Sanofi buys into AZ drug for preventing RSV infections

    The deal also includes up to 495m in development and sales milestone payments and focuses on MEDI8897, a follow-up to AZ's already-marketed Synagis (palivizumab) which is the first ... MEDI8897 is a fully-human antibody that has an extended half-life in

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase IIb.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...